Summary latest Pharmaceutical and Healthcare disease pipeline guide Systemic Mastocytosis - Pipeline Review, H2 2020, provides an overview of the Systemic Mastocytosis (Gastrointestinal) pipeline landscape.
Systemic mastocytosis is a disorder where mast cells are abnormally increased in multiple organs including the bone marrow. Symptoms include shortness of breath, low blood pressure, hives and swelling, itching, diarrhea, headache, flushing and musculoskeletal pain. Treatment includes antihistamines and more aggressive forms of Systemic mastocytosis require interferon or chemotherapeutic agents.
Report Highlights Pharmaceutical and Healthcare latest pipeline guide Systemic Mastocytosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Systemic Mastocytosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Systemic Mastocytosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Systemic Mastocytosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I and Preclinical stages are 1, 5, 4 and 1 respectively.
Systemic Mastocytosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Mastocytosis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Systemic Mastocytosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Systemic Mastocytosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Systemic Mastocytosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Mastocytosis (Gastrointestinal)
Reasons to Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Systemic Mastocytosis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Systemic Mastocytosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
An organ-on-a-chip is a microfluidic cell culture device that contains continuously perfused chambers. This chip develops a narrow channel for the blood and airflow in organs, such as the lung, gut, liver, heart, and other organs. Such devices produce multiple levels of tissue and organ functionalities, which are not feasible using conventional...
Anatomic Pathology Market Report Overview Anatomic Pathology market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Anatomic Pathology market types and applications. It is a focused study on Anatomic Pathology market space including global...
Pathology Devices Market Report Overview Pathology Devices market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Pathology Devices market types and applications. It is a focused study on Pathology Devices market space including global and...
The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period. The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected...
Digital Pathology Market Size, Share & Trends Analysis Report By Product (Software, Device), By Application (Drug Discovery & Development, Academic Research), By End-use, By Region, And Segment Forecasts, 2021 - 2028 Digital Pathology Market Growth & Trends The global digital pathology market...
The global organoids market is expected to reach US$ 3,420.40 million by 2027 from US$ 689.47 million in 2019. The market is estimated to grow at a CAGR of 22.1% from 2020 to 2027. Increasing demand for tumor modelling and biobanking, rising adoption of personalized drugs, and growing focus on developing alternatives for animal testing...
The current practice of medical education and methods of performing surgery and therapy suffer from limitations such as scarcity of subjects to practice on, suboptimal surgical precision, and therapy-related issues including medication misuse and ineffectiveness of the drugs to treat the conditions. Moreover, the outbreak of COVID-19 pandemic...
The global human microbiome market is expected to reach US$ 1,873.53 million by 2027 from US$ 356.29 million in 2019. The market is estimated to grow with a CAGR of 23.6% from 2020 to 2027. The growth of the market is driven by the factors such as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies,...
200 pages •
By The Business Research Company
• Dec 2020
Major players in the anatomical pathology equipment and consumables market are Epridea, F. Hoffmann-La Roche Ltd., Danaher Corporation, Thermo Fisher Scientific, Sakura Finetek, Agilent Technologies, Danaher Corporation, Bio SB, BioGenex Laboratories, and Quest Diagnostics Incorporated. The global anatomic pathology equipment and consumables...
17 pages •
By Euromonitor International
• Feb 2021
Natural increase will be the sole driver of swift population growth in Pakistan in 2020-2040, as net migration remains negative. Ageing will be quite slow over this timeframe, with the country remaining extremely young in a regional context due to relatively elevated birth rates and low life expectancy. Urbanisation will be swift and the country...
Healthcare
Diabetes
Obesity
Pathology
Chronic Disease
Pakistan
World
Life Expectancy
Net Migration Rate
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.